Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer-Reference-Cited by-同舟云学术

Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer

Published:2005-01-26 Issue:1 Volume:23 Page:38-46
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Gleave Martin,Miyake Hideaki

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-004-0474-0.pdf

Reference81 articles.

1. Denis L, Murphy GP (1993) Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72:3888?3895

2. Oh WK, Kantoff PW (1998) Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160:1220?1229

3. Tannock IF, De Wit R, Berry WR et al. for the TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502?1512

4. Petrylak DP, Tangen CM, Hussain MH et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513?1520

5. Isaacs JT, Wake N, Coffey DS, Sandberg AA (1982) Genetic instability coupled to clonal selection as a mechanism for progression in prostatic cancer. Cancer Res 42?48:2353

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The multiple roles and therapeutic potential of clusterin in non-small-cell lung cancer: a narrative review;Translational Lung Cancer Research;2021-06

2. MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer;Biomedicine & Pharmacotherapy;2018-03

3. Patient-derived xenografts: A platform for accelerating translational research in prostate cancer;Molecular and Cellular Endocrinology;2018-02

4. ‘Dual’ peptidyl-oligonucleotide conjugates: Role of conformational flexibility in catalytic cleavage of RNA;Biomaterials;2017-01

5. Clusterin as a therapeutic target;Expert Opinion on Therapeutic Targets;2016-12-16